Diabetes Case Reports

Cell-Replacement Therapy and Pancreatic β-cells in Diabetic Patients

Linjian Qian^* Department of Endocrinology Surgery, Zhejiang University School of Medicine, Hangzhou, China
^*Correspondence: Linjian Qian, Department of Endocrinology Surgery, Zhejiang University School of Medicine, Hangzhou, China, Email:

Received: 02-Jan-2023, Manuscript No. DCRS-23-20871; Editor assigned: 04-Jan-2023, Pre QC No. DCRS-23-20871(PQ); Reviewed: 18-Jan-2023, QC No. DCRS-23-20871; Revised: 25-Jan-2023, Manuscript No. DCRS-23-20871(R); Published: 01-Feb-2023, DOI: 10.35841/2572-5629.23.8.145

Description

Cell replacement therapy for diabetes is a potential treatment that involves creating or transplanting insulin-producing cells to restore normal blood sugar levels in patients with type 1 diabetes. This approach aims to overcome the limitations of current therapies, such as insulin injections or islet transplantation, which require lifelong immunosuppression and have limited availability. Several sources of cell replacement therapy are being explored, such as stem cells, gene therapy, or surrogate cells. Some of these methods have shown promising results in animal models or clinical trials [1].

Stem cell treatment for diabetes is a type of cell replacement therapy that uses stem cells to generate insulin-producing cells that can be transplanted into patients with type 1 diabetes. Stem cells are cells that can develop into different types of cells in the body [2-4]. They can be derived from various sources, such as embryos, adult tissues, or umbilical cord blood. Stem cell treatment for diabetes aims to mimic the function of the pancreatic β-cells that are destroyed by the immune system in type 1 diabetes. Several studies have shown that stem cell-derived insulin-producing cells can secrete insulin in response to glucose and reverse diabetes in animal models. Some clinical trials have also reported promising results in human patients. However, there are still many challenges and limitations inorder to overcome by improving the efficiency and quality of stem cell cell differentiation, avoiding immune rejection or tumor formation, and ensuring long-term functionality and survival of the transplanted cells [5-9].

Some of the risks of stem cell treatment for diabetes are:

• Infection: Stem cells can introduce infection into the body if not handled properly. Infection can also occur at the site of injection or transplantation.

• Blood clots: Blood clots can form in the legs or lungs after a stem cell procedure. This can cause pain, swelling, and potentially life-threatening complications.

• Tumor formation: Stem cells can form tumors if not handled properly. This can happen if the stem cells are not fully differentiated, contaminated, or genetically unstable.

• Rejection: The body may reject the stem cells if they are not compatible with the patient’s immune system. This can cause inflammation, tissue damage, and loss of function.

• Death: Although rare, death can occur as a result of any of the above complications or other unforeseen adverse events.

References

1. Kharroubi AT, Darwish HM. Diabetes mellitus: The epidemic of the century. World J. Diabetes. 2015;6(6):850.

   [Cross Ref] [Google Scholar] [PubMed]

2. D'Amour KA, Bang AG, Eliazer S, Kelly OG, Agulnick AD, Smart NG, et al. Production of pancreatic hormone–expressing endocrine cells from human embryonic stem cells. Nat Biotechnol. 2006;24(11):1392-401.

   [Cross Ref] [Google Scholar] [PubMed]

3. Ma S, Viola R, Sui L, Cherubini V, Barbetti F, Egli D. β cell replacement after gene editing of a neonatal diabetes-causing mutation at the insulin locus. Stem Cell Rep. 2018;11(6):1407-1415.

   [Cross Ref] [Google Scholar] [PubMed]

4. Aguayo-Mazzucato C, Bonner-Weir S. Stem cell therapy for type 1 diabetes mellitus. Nat Rev Endocrinol. 2010;6(3):139-148.

   [Cross Ref] [Google Scholar] [PubMed]

5. Russ HA, Parent AV, Ringler JJ, Hennings TG, Nair GG, Shveygert M, et al. Controlled induction of human pancreatic progenitors produces functional beta‐like cells in vitro. The EMBO journal. 2015;34(13):1759-1772.

   [Cross Ref] [Google Scholar] [PubMed]

6. Lithovius V, Saarimaki-Vire J, Balboa D, Ibrahim H, Montaser H, Barsby T, Otonkoski T. SUR1-mutant iPS cell-derived islets recapitulate the pathophysiology of congenital hyperinsulinism. Diabetologia. 2021;64:630-640.

   [Cross Ref] [Google Scholar] [PubMed]

7. Eizirik DL, Pipeleers DG, Ling Z, Welsh N, Hellerstrom C, Andersson A. Major species differences between humans and rodents in the susceptibility to pancreatic beta-cell injury. Proc Natl Acad Sci. 1994;91(20):9253-9256.

   [Cross Ref] [Google Scholar] [PubMed]

8. Fonseca SG, Gromada J, Urano F. Endoplasmic reticulum stress and pancreatic β-cell death. Trends Endocrinol Metab. 2011;22(7):266-274.

   [Cross Ref] [Google Scholar] [PubMed]

9. Mahaddalkar PU, Scheibner K, Pfluger S, Sterr M, Beckenbauer J, Irmler M, et al. Generation of pancreatic β cells from CD177+ anterior definitive endoderm. Nat Biotechnol. 2020;38(9):1061-1072.

   [Cross Ref] [Google Scholar] [PubMed]

10. Shapiro AJ, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343(4):230-238.

    [Cross Ref] [Google Scholar] [PubMed]

11. Hering BJ, Clarke WR, Bridges ND, Eggerman TL, Alejandro R, Bellin MD, et al. Phase 3 trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia. Diabetes care. 2016;39(7):1230-1240.

    [Cross Ref] [Google Scholar] [PubMed]

12. Delaune V, Berney T, Lacotte S, Toso C. Intraportal islet transplantation: the impact of the liver microenvironment. Transpl Int. 2017;30(3):227-238.

    [Cross Ref] [Google Scholar] [PubMed]